前收市價 | 130.72 |
開市 | 130.13 |
買盤 | 131.22 x 900 |
賣出價 | 131.24 x 800 |
今日波幅 | 130.13 - 131.73 |
52 週波幅 | 99.14 - 133.10 |
成交量 | |
平均成交量 | 8,436,882 |
市值 | 332.815B |
Beta 值 (5 年,每月) | 無 |
市盈率 (最近 12 個月) | 145.99 |
每股盈利 (最近 12 個月) | 0.90 |
業績公佈日 | 2024年4月25日 |
遠期股息及收益率 | 3.08 (2.36%) |
除息日 | 2024年3月14日 |
1 年預測目標價 | 138.98 |
MRK earnings call for the period ending March 31, 2024.
On Thursday, U.S. drug maker Merck & Co Inc (NYSE:MRK) reported first-quarter sales of $15.8 billion, up 9% year-over-year, beating the consensus estimate of $15.2 billion. Excluding the impact of foreign exchange, sales increased 24%. Merck reported adjusted EPS of $2.07, up 48%Y/Y, beating the consensus of $1.88. Merck’s pharmaceutical unit booked $14.01 billion in revenue during the first quarter, up 10% Y/Y. Related: Merck’s $11B Bet Pays As FDA Approves Sotatercept For Rare Lung Disease. Me
Merck (MRK) beats first-quarter estimates for earnings and sales. The company raises its EPS range for 2024. Stock rises in pre-market.